CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 617 enrolled
Drug / intervention
Bepotastine besilate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01753739
NCT01753739Phase 2Completed
CompareCT.gov

A Dose-Ranging Study to Evaluate the Safety and Efficacy of Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects With a Demonstrated History of Mountain Cedar Pollen Allergic Sensitivity

Bausch & Lomb Incorporated·interventional·Posted Dec 20, 2012·Updated Oct 5, 2020

In Brief

A Phase 2 clinical trial evaluating Bepotastine besilate and Placebo for Seasonal Allergic Rhinitis. Completed, enrolled 617 participants across 1 site.

Detailed Summary

This study will examine dose ranging characteristics of bepotastine besilate nasal spray compared to placebo nasal spray in 600 male or female subjects 12 years of age and older with active seasonal allergic rhinitis (SAR) and a demonstrated history of allergic sensitivity to Mountain Cedar pollen for at least 2 years prior to the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 20, 2012
Enrollment StartJan 1, 2013
Primary CompletionFeb 1, 2013
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.5 years ago

Interventions

Bepotastine besilatedrug

Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days

Placebodrug

Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days